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Abstract In women, there is evidence that a single nucleotide polymorphism (SNP) in the histidine-rich glycoprotein (HRG) named
HRG C633T is relevant for a number of fertility outcomes including recurrent miscarriage, ovarian response and pregnancy outcome
after IVF. This case-control study was designed to investigate whether the HRG C633T SNP is important for male infertility and preg-
nancy rate following IVF. Cases were 139 infertile couples and controls were 196 pregnant couples. The 335 couples all contributed
with one blood sample per partner. Genomic DNA was extracted and genotyping was performed using a TaqMan® SNP Genotyping
Assay. Information on pregnancy rate and semen parameters was derived from medical records. Infertile couples in which the male
partner was a homozygous carrier of the HRG C633T SNP had signiﬁcantly lower (P < 0.01) pregnancy rate following IVF in compari-
son with couples where the male partner was a heterozygous HRG C633T SNP carrier. Male homozygous HRG 633T SNP carriers had
overall lower total sperm count, sperm concentration, motility score and yield after preparation. In conclusion, once infertility is
established the HRG C633T SNP seems to be important for male infertility and pregnancy rate following IVF.
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Introduction
Infertility affects approximately 15% of couples around the
world, and the underlying causes can be grouped into male
factors, female factors and unexplained infertility (Kamath
and Bhattacharya, 2012). Among these, male infertility, alone
or combined with female factors, accounts for up to 50% of
cases (Esteves et al., 2012). Many infertile couples are helped
by IVF, which remains the treatment of choice in long-
standing, unresolved infertility (Kamath and Bhattacharya,
2012).
Many factors, such as patient age, body mass index (BMI),
smoking and previous surgery (Andersen et al., 2015; Esteves
et al., 2012; Pinborg et al., 2011; Waylen et al., 2009), affect
a couple’s response to assisted reproductive treatment.
Genetic make-upmay also inﬂuence the response and outcome
of assisted reproductive treatment (Venkatesh et al., 2014).
It is estimated that 10–15% of spermatogenic impairment is
explained by genetic defects (Ferlin and Foresta, 2014), and
furthermore, association studies propose gene polymor-
phisms to affect spermatogenesis, which in turn may lead to
oligozoospermia- or azoospermia-inducedmale infertility (Chen
et al., 2015; Ge et al., 2015; Plaseski et al., 2012; Sato et al.,
2015).
We have previously shown that a genetic variant of the
histidine-rich glycoprotein (HRG) gene may be relevant for
pregnancy success rate following IVF (Nordqvist et al., 2011b)
but also for recurrent miscarriage (Lindgren et al., 2013). This
single nucleotide polymorphism (SNP) is denoted HRG C633T
and has either a cytosine (C) or a thymine (T) at position 633
in the gene. The result of the HRG C633T SNP is a missense
variation where a cytosine codes for a proline amino acid and
a thymine will instead code for a serine at position 186 in the
protein. The serine allows for a glycosylation at position 184
in the protein. The HRG C633T SNP is relatively common, with
allele frequencies of 67% and 33% for C and T, respectively,
in a mixed European population [http://www.ensembl.org/
Homo_sapiens, rs9898]. HRG is a multi-domain protein that
is synthesized by the liver and is present at high levels in
plasma, where it seems to function as an adaptor protein. HRG
is involved in coagulation, angiogenesis and the immune system
(Jones et al., 2005; Poon et al., 2010; Wakabayashi, 2013),
all of which are processes important for establishment of a
pregnancy (Bazer et al., 2010; Thornton and Douglas, 2010).
In addition, HRG interacts with thrombospondin, plasmin and
plasminogen, IgG, ﬁbrinogen, heparin, vascular endothelial
growth factor (VEGF) and various members of the ﬁbroblast
growth factor (FGF) family (Gorgani et al., 1997; Jones et al.,
2004; Lerch et al., 1988; Simantov et al., 2001; Vu et al., 2011;
Wakabayashi and Koide, 2011; Wake et al., 2009). Again, many
of these ligands have been associated with infertility (Cotton
et al., 2008; Ebisch et al., 2008; Lash et al., 2012).
We have previously demonstrated that women with un-
explained infertility who were homozygous T/T-carriers of the
SNP (HRG 633T SNP) had lower than expected pregnancy rates
following IVF. Correspondingly in another study, the homo-
zygous HRG 633T SNP carriers had fewer oocytes retrieved
despite higher levels of administered FSH, even though rel-
evant demographic factors such as age, antral follicle count
and anti-Müllerian hormone (AMH) levels were similar between
groups (Nordqvist et al., 2015). However, it has not been
established whether the SNP is more common in infertile
couples than in pregnant control couples, and furthermore,
no studies have investigated this SNP in relation to male in-
fertility and semen parameters. Thus, the aim of this study
was to investigate whether male HRG C633T genotype is as-
sociated with pregnancy rate following IVF and semen pa-
rameter values in infertile couples. A secondary aim was to
explore whether the HRG C633T SNP distribution is differ-
ent between infertile couples and a control population of preg-
nant couples without infertility history.
Materials and methods
Ethics
The study was approved by the Regional Ethics Review Board
in Stockholm (diary numbers: 2007/3–31/3, 2007/1559–32,
approval 7 March 2007; 2010/0180–32, amendment ap-
proval 12 February 2010). All couples met with a healthcare
professional and received written and verbal information about
the study and gave written informed consent. Participation
was voluntary, not reimbursed and did not affect treatment.
Study population
Heterosexual couples visiting an IVF clinic (Fertilitetscentrum,
Stockholm) between 1 March 2010 and 6 February 2012 were
asked to participate in the study. The answering frequency
is not known. Couples were ﬂuent in Swedish or English and
contributed with one blood sample per person. Blood samples
were collected on the day of ovum pick-up. All couples had
previously undergone assessment for cause of infertility.
Infertile women were screened for anovulation, includ-
ing polycystic ovarian syndrome (PCOS), according to Rot-
terdam criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS
consensus workshop group, 2004), thyroid dysfunction, tubal
factors, endometriosis and uterine anomalies. Basal FSH levels
or AMH levels were tested, and FSH levels below 13 IU/l or
AMH levels above 0.7 ng/ml were considered normal.
Infertile men were screened for previous infections (in
testis, epididymis and prostate), previous surgery (inguinal
hernia, genital tract or urinary tract) and medical history. Male
BMI was not available. Semen analyses were routinely per-
formed by embryologists and included the number of and mo-
tility of spermatozoa. Normally, only one semen sample is
analysed during a fertility investigation at this clinic, but if
the results are deviant the test is repeated. Sperm counts
below the World Health Organization guideline levels (Tocci
and Lucchini, 2010) were classiﬁed as male infertility. A mo-
tility score was used, ranging from zero to three, where zero
deﬁnes immobile spermatozoa and three corresponds to the
highest progressive motility.
Couples were included regardless of infertility diagnosis
even if the infertility was unexplained or had multiple causes.
Overall, 155 couples consented to participate. Among these,
genotyping was completed in 139 couples. The couple’s in-
fertility diagnoses are listed in Table 1.
Obstetric and medical history of the infertile couples is dis-
played in Supplementary Table S1. About one-ﬁfth of couples
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had been pregnant before (22.3%) and almost one-ﬁfth (18.7%)
had experienced at least one miscarriage. Only two out of the
139 couples (1.4%) had a child together. The frequencies of
previous pregnancies and miscarriages were about the same
among men and women but a higher proportion of men had
a child from a previous or current relationship (14.4% versus
5.0%, P < 0.05). Hypothyroidism was reported in eight women
(5.8%), diabetes (type 1 or type 2 not speciﬁed) in two
women and one man, and thrombophilia in two women.
Supplementary Table S2 displays previous surgery and in-
fections of the infertile men. Surgery for inguinal hernia, tes-
ticular disorders and varicocele was reported by 18 men.
Infections of epididymis and prostate were reported by six
men, and eight men had a history of chlamydia. Semen test
results were available for all but two men (n = 137).
The control group consisted of heterosexual pregnant
couples without previous infertility, who were approached in
gestational week 16–19, in conjunction with the routine ul-
trasound scan at Uppsala University Hospital, between Feb-
ruary 2012 and December 2012. Control couples were 18 years
of age or older, had conceived spontaneously and were able
to understand Swedish or English. Each couple contributed
with one blood sample per person on the day of the ultra-
sound scan. In total, 196 control couples were included and
genotyping was successful in all. The women’s medical records
were reviewed for data on age, weight, height and smoking/
snuff habits from their admission to the maternity centre in
the ﬁrst trimester. Female demographic data such as BMI and
smoking/snuff habits were not entirely comparable to the
infertile couples because the latter group was not pregnant
at the time of enrolment. Male BMI and smoking/snuff habits
were not available.
IVF treatment
The IVF treatment protocols at the Fertilitetscentrum Stock-
holm have previously been described in detail (Nordqvist et al.,
2015). In brief, starting dosages of FSH were determined in-
dividually based on anticipated ovarian response and, when-
ever possible, on previous treatment results. Ultrasound
evaluation began on stimulation day 5–10 and was repeated
if necessary. Dosages could be changed at the ultrasound de-
pending on results. Women underwent either a gonadotrophin-
releasing hormone (GnRH) agonist protocol (n = 108) or GnRH
antagonist protocol (n = 31). The women received recombi-
nant FSH (n = 114) or human menopausal gonadotrophins
(HMG) (n = 25). Only ejaculated partner spermatozoa were
used. Intracytoplasmic sperm injection (ICSI) was used if the
number of prepared spermatozoa using PureSperm® (Nidacon,
Sweden) was ≤1 million or in cases with previous low fertil-
ization (<50%). Conventional IVF (n = 95), ICSI (n = 38) or a
combination of both (n = 5) were used. Embryos were as-
sessed according to standardized clinical morphological pro-
tocols (Alpha Scientists in Reproductive Medicine and ESHRE
Special Interest Group of Embryology, 2011), and transfer was
not performed if there were signs of abnormal growth. Single-
embryo transfer was performed in most cases (n = 110) and
double-embryo transfer was performed if the risk of having
twins was low (n = 9).
Table 1 Treatment and causes of infertility, in the total study population and according to male HRG C633T SNP.
Total sample Male HRG C633T SNP
C633 C633T 633T
n = 139 n = 72 n = 51 n = 16
Cause of infertility
Anovulatory 15 (10.8) 8 (11.1) 5 (9.8) 2 (12.5)
Tubal factor 10 (7.2) 7 (9.7) 3 (5.9) 0
Endometriosis 7 (5.0) 3 (4.2) 4 (7.8) 0
Unexplained 68 (48.9) 35 (48.6) 25 (49.0) 8 (50.0)
Male infertility 26 (18.7) 9 (12.5) 12 (23.5) 5 (31.3)
Multiple diagnosesa 10 (7.2) 7 (9.7) 2 (3.9) 1 (6.3)
Other 3 (2.2) 3 (4.2) 0 0
Male infertility as single or combined factor 35 (25.2) 15 (20.8) 14 (27.5) 6 (37.5)
Infertility duration (years) 2.5 (2.0–3.5) 2.5 (2.0–3.25) 2.5 (2.0–3.5) 2.5 (1.6–3.0)
Total treatmentsb 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–1.0)c 1.5 (1.0–2.75)
IVF 96 (69.1) 50 (69.4) 37 (72.5) 9 (56.3)
ICSI 36 (25.9) 20 (27.8) 11 (21.6) 5 (31.3)
Combined IVF/ICSI 7 (5.0) 2 (2.8) 3 (5.9) 2 (12.5)
Embryos from IVF transferred 81 (58.3) 40 (55.6) 34 (66.7) 7 (43.8)
Embryos from ICSI transferred 38 (27.3) 20 (27.8) 13 (25.5) 5 (31.3)
No embryo transfer 20 (14.4) 12 (16.7) 4 (7.8) 4 (25.0)
Data are presented as median (interquartile range) or number (%).
IVF = conventional IVF; ICSI = intracytoplasmic sperm injection.
aIncluding both male/female causes and couples with only multiple female causes and no male cause.
bTotal treatments including the current treatment.
cSigniﬁcantly lower than homozygous C633 and 633T, P < 0.01, respectively, Kruskal–Wallis and post hoc Mann–Whitney U-test.
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Among infertile couples, 51 (36.7%) became pregnant after
treatment, 68 (48.9%) did not become pregnant, and 20 (14.4%)
couples had no embryo transfer for reasons mostly related to
pathological development of the embryo or no oocytes being
fertilized (n = 16, 80.0%). Four couples did not have an embryo
transfer due to a risk of ovarian hyperstimulation syndrome
(n = 2), for social reasons (n = 1) and due to technical difﬁ-
culties with the transfer (n = 1).
Blood sampling and DNA extraction
Venous blood samples were collected in EDTA-containing tubes
on the day of ovum pick-up for the infertile couples and at
the ultrasound scan for the controls. All samples from both
groups were handled equally. After a centrifugation step
(1500g for 10 min), buffy coat was transferred to new tubes
and stored at −20°C until transferred weekly to −70°C storage.
The buffy coat from 16 of the infertile couples was dis-
carded by accident and therefore it was not possible to
perform the subsequent analyses on these. Genomic DNA was
extracted from the buffy coat using QIAamp DNA Blood Mini
Kits (Qiagen, Venlo, The Netherlands).
Genotyping
Genotype was determined after embryo transfer. The samples
were genotyped for the HRG C633T SNP (rs9898), using the
TaqMan® SNP Genotyping Assay and run with the StepOnePlus
real-time PCR system (Life Technologies Inc.). Brieﬂy, poly-
merase chain reactions were performed in 96-well plates in
a total volume of 25 μl for each reaction. Each reaction con-
sisted of 1 × TaqMan Universal PCR Master Mix (PCR buffer,
ROX passive reference dye, dNTPs and AmpliTaq Gold DNA
Polymerase), 1 × SNP Genotyping Assay (sequence-speciﬁc
forward and reverse primers to amplify the polymorphic se-
quence of interest, i.e. HRG exon 5, TaqMan MGB probes la-
belled with VIC dye to detect allele 1 sequence and with FAM
to detect allele 2 sequence) and 10 ng of genomic DNA. Cycling
conditions were initiated for 10 min at 95°C followed by 40
cycles of 15 s at 92°C and 1 min at 60°C. Real-time ﬂuores-
cence detection was performed. StepOne™ Software (Life
Technologies Inc.) was used to plot ﬂuorescence (Rn) values
based on the signals from each well. The plotted ﬂuores-
cence signals indicated which alleles were present in each
sample.
Statistics
Couples in whom embryo transfer was not performed due to
pathological development of the embryo or no oocytes being
fertilized (n = 16, 80.0%) were included in the non-pregnant
group. The four couples who did not have an embryo trans-
fer, for other reasons, were excluded.
The number of homozygous and heterozygous carriers of
the HRG C633T SNP was in Hardy–Weinberg equilibrium
(X2 = 0.114). For skewed data, the Kruskal–Wallis test was em-
ployed, followed by post hoc Mann–Whitney U-test. Categori-
cal data were analysed with the Pearson chi-squared test or
Fisher’s exact test. All statistical tests were two-sided and
P-values of <0.05 were considered signiﬁcant. The Statisti-
cal Package for the Social Sciences version 20.0 was used for
all statistical analysis (IBM Corp., USA).
Results
Background characteristics and frequency of the
HRG C633T SNP
In total, 139 infertile and 196 pregnant couples were in-
cluded in the study. The infertile women and men were older
than the corresponding controls (women; 34 (31–36) versus
31 (27–34) years; P < 0.001 and men; 36 (33–39) versus 32
(29–35) years; P < 0.001). Across the HRG C633T SNP no dif-
ferences in age, BMI, smoking or snuff usage were noted
(Supplementary Table S3). The distribution of the HRG C633T
SNP did not differ between infertile women and men and their
respective controls (Table 2). Furthermore, no difference in
frequency of T-alleles between infertile and control couples
was noted (Figure 1). However, men diagnosed with male
factor infertility (as single factor) were more often homozy-
gous HRG 633T SNP carriers than men in the pregnant control
group, but this was only borderline signiﬁcant (HRG 633T SNP;
male factor infertility 19.2% versus control men 7.1%; P = 0.05).
Table 2 Frequency of the HRG C633T SNP in infertile men and
women, and respective controls.
Men Women
Infertile Control Infertile Control
n = 139 n = 196 n = 139 n = 196
HRG C633T
C633, n (%) 69 (49.6) 97 (49.5) 72 (51.8) 108 (55.1)
C633T, n (%) 57 (41.0) 78 (39.8) 51 (36.7) 74 (37.8)
633T, n (%) 13 (9.4) 21 (10.7) 16 (11.5) 14 (7.1)
No signiﬁcant differences in genotype frequencies noted, Pearson chi-
squared test.
Figure 1 T-allele frequency of the HRG 633T SNP in infertile and
pregnant control couples. No difference in frequency of T-alleles
between infertile and control couples was noted, Pearson chi-
squared test.
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IVF treatment and pregnancy rate
Detailed information on the infertile women’s IVF treat-
ment parameters in relation to the different HRG C633T SNPs
has been presented previously (Nordqvist et al., 2015). Brieﬂy,
no differences were found except that women who were ho-
mozygous HRG 633T SNP carriers needed signiﬁcantly higher
FSH dosages during treatment than the others (Nordqvist et al.,
2015).
Among the infertile men no differences in infertility di-
agnoses, treatment type or number of embryo transfers were
found across the homozygous and heterozygous carriers of the
HRG C633T SNP (Table 1). However, the male heterozygous
HRG C633T SNP carriers had undergone fewer previous IVF/
ICSI treatments than the other groups, P < 0.01 (Table 1).
TheHRGC633T SNPwas not associatedwith pregnancy rate
in the infertilewomen;however, in infertilemen theHRGC633T
SNP had an impact on the pregnancy rate of the current treat-
ment cycle (Table 3). Most successful were couples withmale
heterozygositywhere 52.0% achieved pregnancy,whereas only
two couples (14.3%) became pregnant when the male part-
ners were homozygous carriers of theHRG 633T SNP, P < 0.01.
These results remained even when couples with no embryo
transfer were excluded from the analysis (data not shown).
Figure 2 shows the pregnancy rate in relation to the fre-
quency of T-alleles in the infertile couples. Most successful
were couples with one or two T-alleles, which corresponds
to one or two heterozygous HRG 633T SNP carriers or only one
homozygous HRG 633T SNP carrier in the couple, where 48.1%
(n = 26) and 42.1% (n = 16) became pregnant, respectively
(Figure 2A). Couples carrying no or three T-alleles in the HRG
C633T SNP had a low pregnancy rate; only 20% (n = 7) of
couples with no T-alleles and 16.7% (n = 2) of couples with
three T-alleles became pregnant. Figure 2B displays preg-
nancy rate in the couples in which either partner was homo-
zygous for the T-allele. While the numbers were too low for
statistical comparisons it is noted that couples in which the
woman was a homozygous HRG 633T SNP carrier were most
successful. When two T-alleles were present in the couple and
the woman was homozygous, 37.5% (n = 3) became preg-
nant compared with 22.2% (n = 2) if the man was carrying the
homozygosity. When three T-alleles were carried by the
couple, 40% (n = 2) became pregnant if the woman was ho-
mozygous and none if the man was homozygous.
Table 3 Treatment outcome according to HRG C633T SNP.
Men, n = 135a Women, n = 135a
Pregnant Not pregnantb Pregnant Not pregnantb
In total, n (%) 51 (37.8) 84 (62.2) 51 (37.8) 84 (62.2)
HRG C633T, n (%)
C633 23 (32.4) 48 (67.6) 22 (33.3) 44 (66.7)
C633T 26 (52.0) 24 (48.0) 24 (42.9) 32 (57.1)
633T 2 (14.3) 12 (85.7)** 5 (38.5) 8 (61.5)
**P < 0.01, Pearson chi-squared test.
aFour patients are excluded due to no embryo transfer for reasons other than pathological de-
velopment of the embryo or no oocytes being fertilized.
bPatients with no embryo transfer due to pathological development of the embryo or no oocytes
being fertilized are included in the non-pregnant group (n = 16).
Figure 2 Pregnancy rate following IVF according to the frequency of T-alleles (HRG 633T SNP) in the infertile couples. Bars repre-
sent the percentage of pregnant couples according to the number of T-alleles within the couple. The total number of couples is given
within each bar. (A) All pregnant couples. No couples had four T-alleles (homozygous 633T/633T), hence this bar is not shown.
(B) Couples with one homozygous HRG 633T SNP carrier; either the woman (grey) or the man (white). Due to the small numbers no
statistical analyses were performed. *P < 0.05, **P < 0.01, Pearson chi-squared test.
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Semen proﬁle
The semen proﬁle of 137 infertile men, according to the male
HRG C633T SNP, is displayed in Table 4. Male homozygous HRG
633T SNP carriers had lower total sperm count and motility
score compared with both homozygous HRG C633 SNP carri-
ers and heterozygous HRG C633T SNP carriers. Moreover,
homozygous HRG 633T SNP carriers had lower sperm concen-
tration and yield after preparation compared with homozy-
gous HRG C633 SNP carriers (Table 4). A sensitivity analysis,
excluding all men with male factor infertility, rendered similar
results, except for yield after preparation, which no longer
remained signiﬁcantly different across the HRG C633T SNP
(data not shown).
Discussion
In women, the HRG C633T SNP has previously been shown to
be relevant for a number of fertility outcomes (Lindgren et al.,
2013; Nordqvist et al., 2011a), but its role in infertile men,
and infertile couples, has until now not been investigated.
Our ﬁndings suggest that the HRG C633T SNP is equally dis-
tributed in infertile and pregnant control couples. This ﬁnding
is not unexpected as infertility has many causes and is not
considered a Mendelian inherited disease. However, once in-
fertility is established the HRG C633T SNP seems to play a role;
couples with male homozygous carriers of the HRG 633T SNP
had a lower chance of a successful treatment, and male ho-
mozygous HRG 633T SNP carriers had the overall lowest semen
parameter values.
When analysing the infertile couples, two important ﬁnd-
ings in regard to the expression of the HRG C633T SNP were
revealed. First, couples carrying oneor twoT-alleles hadhigher
pregnancy rates in comparison with couples with no T-allele
present. This implies that the T-allele is needed in at least
one copy in the couple for a higher chance of pregnancy. Sec-
ondly, in couples withmore than two copies, i.e. with at least
onepartner being homozygous for theT-allele, pregnancy rates
declined to 16.7%. As previously stated, this was especially
relevant in couples withmale homozygous carriers of theHRG
633T SNP, where pregnancy rates were 0% or 22%, depending
on whether the female partner had a T-allele or not. Hence,
male HRG C633T SNP heterozygosity was superior in terms of
IVF treatment outcomeandwas also associatedwith the lowest
number of total treatments compared with the homozygous
carriers. This is in line with the theory of heterozygote ad-
vantage inwhich heterozygous carriers present a selective ad-
vantage in viability and reproductive ﬁtness over homozygotes
in natural populations (Hansson and Westerberg, 2002). This
theory hasmostly been associatedwith disease resistance but
is also described in relation to female fecundity. Laanpere
et al. (2011) investigated infertilewomenundergoing IVF treat-
ment and the importance of several different SNPs in the folate
pathway. They reported positive associations between het-
erozygous carriers and different outcome parameters such as
good-quality embryos and increased chance of pregnancy
(Laanpere et al., 2011). Elenis et al. (2014) found that fewer
womenwhowere heterozygous carriers of another SNP in the
HRG gene (A1042G) had recurrent miscarriage.
There are several reasons why the HRG C633T SNP may
confer heterozygous advantage. First, the predominant/
native HRG protein contains a proline at amino acid 186 (cor-
responding to the HRG C633 SNP). Proline is thought, due to
its unique cyclical formation with a secondary amine, to be
important for the protein structure and contributes to ex-
ceptional conformational rigidity. The variant protein that has
a serine at amino acid 186 (corresponding to the HRG 633T
SNP) allows for a glycosylation at position 184 in the protein
(Jones et al., 2005; Kassaar et al., 2014). In between the po-
sition in the protein where the amino acid shift might occur
and the extra glycosylation an inter-domain disulphide bridge
is found (amino acid 185). With the proline186serine shift and
the interference of the glycosylationwith the disulphide bridge
nearby,HRGcouldbe less stableor its function couldbealtered.
If the variant HRG protein possesses functions somewhat dif-
ferent from the predominant/native protein, the heterozy-
gous genotype could beneﬁt from having both. Secondly, the
disulphide bridge connects to a region in the protein known
to have angiogenesis-regulating properties. It has been shown
that a fragment from this region can, when released from the
protein, exert an anti-angiogenic effect on endothelial cells
via different mechanisms (Dixelius et al., 2006; Hennis et al.,
1995; Kassaar et al., 2014; Lee et al., 2006). HRG in its pre-
dominant form can inhibit both VEGF and FGF-mediated an-
giogenesis of endothelial cells in vitro (Olsson et al., 2004)
but in the variant of the HRG protein where an amino acid
Table 4 Semen parameters of 137 infertile men, according to male HRG C633T.
HRG C633T
C633, n = 72 C633T, n = 49 633T, n = 16
n Median (range) n Median (range) n Median (range)
Ejaculate volume (ml) 72 2.5 (2.0–4.0) 49 3.1 (2.6–4.0)a 16 2.5 (1.6–3.5)
Total sperm count (106) 72 131 (57–247) 49 180 (63–274) 16 81 (38–106)a,b
Sperm concentration (×106/ml) 72 52.0 (29–85) 49 52 (23–85) 16 28 (14–50)a
Progressive motility (%) 72 59 (45–71) 48 62 (44–70) 15 65 (40–70)
Motility score (0–3) e 64 2.3 (2.2–2.4) 38 2.3 (2.2–2.4) 15 2.2 (2.0–2.3)a,b
Yield after preparation (%) 72 10.0 (2.5–20.0) 49 7.5 (1.2–20.5) 16 2.5 (0.6–10.1)a
aSigniﬁcantly different from homozygous C633, P < 0.05–0.01, Kruskal–Wallis and post hoc Mann–Whitney U-test.
bSigniﬁcantly different from heterozygous C633T, P < 0.05–0.01, Kruskal–Wallis and post hoc Mann–Whitney U-test.
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shift has occurred in position 186 the stability of the disulphide
bridge might be altered and thereby disable the proteolytic
release of the anti-angiogenic fragment. Finally, HRG is also
known to have an indirect pro-angiogenic effect via the binding
of thrombospondins (TSP) (Simantov et al., 2001). TSP exert
their anti-angiogenic effect through binding of the CD36-
receptor on endothelial cells and by inhibiting the response
of a number of different growth factors important for angio-
genesis such as FGF and VEGF (Febbraio et al., 2001). Indeed,
a proteome analysis has located TSP1 and TSP2 to the testis,
prostate and seminal vesicles of men (Wilhelm et al., 2014).
HRG contains two CD36 homology domains and one of them
is located around the polymorphic area (amino acid 155–213),
that binds to TSP with high afﬁnity, thereby blocking its anti-
angiogenic activity (Jones et al., 2005; Simantov et al., 2005).
The pro- and anti-angiogenic effects mentioned above could
be lacking in the less common variant of the protein and so
possibly contribute to the lower pregnancy rates seen in couples
with male homozygous carriers of the HRG 633T SNP.
Male homozygous HRG 633T SNP carriers had overall
lower semen test results. Furthermore, when men with male
infertility were excluded the total sperm count, sperm con-
centration and motility score remained the lowest among
carriers of the homozygous HRG 633T SNP. We have recently
described that HRG exists in the female reproductive tract
and also in human blastocysts (Nordqvist et al., 2010), but
the presence and distribution of HRG in themale genital tract
is not as well investigated. However, by mass spectrometry
the HRG protein has been detected in the testis, prostate and
seminal vesicles of thehumanmalegenital tract (Wilhelmetal.,
2014), where it potentially could inﬂuence spermatogenesis.
Normal spermatogenesis requires crosstalk between somatic
andgermcells, relevant endocrine signalling (SinghandJaiswal,
2011) and adequate blood ﬂow (Ebisch et al., 2008). Vascu-
lar changes have been reported in testicular biopsies from in-
fertile men (Cummins et al., 1994; Nasah and Cox, 1978), and
potentially for the reasons given above, HRGmay act as a regu-
lator of angiogenesis during spermatogenesis and matura-
tion of spermatozoa. It is known that transcripts and proteins
important for early embryogenesis accompany the male DNA
and are introduced to the oocyte through the spermatozoon
(Jodar et al., 2016). It is possible that this set of transcripts
and proteins can be altered by the milieu in which the sper-
matozoa are produced. The effect of this could be reﬂected
in the characteristicsmeasured in the spermanalysis but could
also go unnoticed in couples without a male factor infertil-
ity. HRG also inﬂuences vascular endothelial growth factor
(VEGF), another key player in angiogenesis, which is ex-
pressed by both Leydig and Sertoli cells in prostate vesicles,
and in seminal vesicles (Olsson et al., 2004) Ergun et al., 1997).
Importantly, VEGF is present in high levels in seminal plasma
(Brown et al., 1995). Obermair et al. (1999) found the con-
centration of VEGF in seminal plasma to be the strongest pre-
dictor of the chance of pregnancy in IVF treatment, and they
also reported that spermatozoa have receptors for VEGF.While
the function of VEGF in the male genital tract is unclear, it
appears to inﬂuence the testicular microvasculature and the
composition of seminal plasma. Taken together it might be
that the heterozygous carriers of the HRG C633T SNP are fa-
voureddue toamorebalanced regulationof angiogenesis during
spermatogenesis through different pro- and/or anti-angiogenic
actions depending on the HRG C633T SNP, and that this
regulation is suboptimal in the homozygousHRG 633T SNPmen.
It is also possible that HRG exerts a direct effect on the sper-
matozoa and not through its action as an adaptor molecule.
Our ﬁndings add to the growing literature on genetic
reasons for infertility (Chen et al., 2015; El Inati et al., 2012;
Ferlin and Foresta, 2014; Ge et al., 2015; Plaseski et al., 2012;
Sato et al., 2015). It is well known that both autosomal and
sex chromosome genes are involved in the complex regula-
tion of spermatogenesis (Guo et al., 2012; Singh and Jaiswal,
2011). However, non-syndromic autosomal gene defects may
also result in male infertility, with mutations in the SPATA16,
PICK1 and DPY192L2 genes and SNPs in the PRMT6, PEX10 and
SOX5 genes being associated with sperm defects or spermato-
genesis (El Inati et al., 2012). Male autosomal chromosome
variation, i.e. differences in size or staining of chromosome
segments, has been negatively associated with fertilization
rate (Liang et al., 2014) and clinical pregnancy rate (Guo et al.,
2012; Singh and Jaiswal, 2011) following IVF, whereas such
ﬁndings in women had no inﬂuence. In addition, a polymor-
phism in the paternal or maternalmethylenetetrahydrofolate
reductase (MTHFR) gene was associated with recurrent preg-
nancy loss (Vanilla et al., 2015), Ozdemir et al., 2012).
A limitation with this study is the low number of couples
withmale factor infertility as the single reason for treatment,
which makes it impossible to draw any ﬁnal conclusions, but
the results are interesting and generate well-deﬁned hypoth-
eses to be investigated in a prospective cohort study with a
larger setting in the future. In addition to the many reasons
for infertility, the complex nature of these types of studies is
underscored by the fact that each individual of the couple
contributes with intricate genetic, proteomic and metabolic
differences that interact (Kovac et al., 2013), and as noted
in the present study, sub-fertility cannot be simply ex-
plained by one single causative polymorphism. Apparently,
the exact role of HRG in reproduction remains to be inves-
tigated, but we can add to the puzzle that infertile couples
where the male partner is homozygous for the HRG 633T SNP
have lower semen quality and are at risk of not having a suc-
cessful IVF treatment.
Acknowledgements
The authors thank research nurse Jane Fred Grafström at the
Department of Women’s and Children’s Health, Uppsala Uni-
versity, for her work with the inclusion of the pregnant control
couples. This work was supported by grants from the Swedish
Research Council (D0277902 and D0277901), the Swedish
Society of Medicine and Stiftelsen Olle Engkvist Byggmästare,
Stockholm, Sweden.
Appendix: Supplementary material
Supplementary data to this article can be found online at
doi:10.1016/j.rbmo.2016.05.004.
References
Alpha Scientists in Reproductive Medicine and ESHRE Special Inter-
est Group of Embryology, 2011. The Istanbul consensus workshop
186 KE Lindgren et al.
on embryo assessment: proceedings of an expert meeting. Hum.
Reprod. 26, 1270–1283.
Andersen, J.M., Herning, H., Aschim, E.L., Hjelmesaeth, J., Mala,
T., Hanevik, H.I., Bungum, M., Haugen, T.B., Witczak, O., 2015.
Body mass index is associated with impaired semen characteris-
tics and reduced levels of anti-mullerian hormone across a wide
weight range. PLoS ONE 10, e0130210.
Bazer, F.W., Wu, G., Spencer, T.E., Johnson, G.A., Burghardt, R.C.,
Bayless, K., 2010. Novel pathways for implantation and estab-
lishment and maintenance of pregnancy in mammals. Mol. Hum.
Reprod. 16, 135–352.
Brown, L.F., Yeo, K.T., Berse, B., Morgentaler, A., Dvorak, H.F.,
Rosen, S., 1995. Vascular permeability factor (vascular endothe-
lial growth factor) is strongly expressed in the normal male genital
tract and is present in substantial quantities in semen. J. Urol.
154, 576–579.
Chen, X.Y., Chen, P., Xu, C., Zhang, X.H., 2015. Association of DAZL
A260G and A386G polymorphisms with oligozoospermia- or
azoospermia-induced male infertility: a meta-analysis]. Zhonghua
Nan Ke Xue. 21, 345–356.
Cotton, L.M., O’bryan, M.K., Hinton, B.T., 2008. Cellular signaling
by ﬁbroblast growth factors (FGFs) and their receptors (FGFRs)
in male reproduction. Endocr. Rev. 29, 193–216.
Cummins, J.M., Jequier, A.M., Kan, R., 1994. Molecular biology of
human male infertility: links with aging, mitochondrial genet-
ics, and oxidative stress? Mol. Reprod. Dev. 37, 345–362.
Dixelius, J., Olsson, A.K., Thulin, A., Lee, C., Johansson, I., Claesson-
Welsh, L., 2006. Minimal active domain and mechanism of action
of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer
Res. 66, 2089–2097.
Ebisch, I.M., Thomas, C.M., Wetzels, A.M., Willemsen, W.N., Sweep,
F.C., Steegers-Theunissen, R.P., 2008. Review of the role of the
plasminogen activator system and vascular endothelial growth
factor in subfertility. Fertil. Steril. 90, 2340–2350.
El Inati, E., Muller, J., Viville, S., 2012. Autosomal mutations and
human spermatogenic failure. Biochim. Biophys. Acta 1822, 1873–
1879.
Elenis, E., Lindgren, K.E., Karypidis, H., Skalkidou, A., Hosseini, F.,
Bremme, K., Landgren, B.M., Skjoldebrand-Sparre, L., Stavreus-
Evers, A., Sundstrom-Poromaa, I., Akerud, H., 2014. The histidine-
rich glycoprotein A1042G polymorphism and recurrent miscarriage:
a pilot study. Reprod. Biol. Endocrinol. 12, 70.
Ergun, S., Kilic, N., Fiedler, W., Mukhopadhyay, A.K., 1997. Vascu-
lar endothelial growth factor and its receptors in normal human
testicular tissue. Mol. Cell. Endocrinol. 131, 9–20.
Esteves, S.C., Hamada, A., Kondray, V., Pitchika, A., Agarwal, A.,
2012. What every gynecologist should know about male infertil-
ity: an update. Arch. Gynecol. Obstet. 286, 217–229.
Febbraio, M., Hajjar, D.P., Silverstein, R.L., 2001. CD36: a class B
scavenger receptor involved in angiogenesis, atherosclerosis, in-
ﬂammation, and lipid metabolism. J. Clin. Invest. 108, 785–791.
Ferlin, A., Foresta, C., 2014. New genetic markers for male infer-
tility. Curr. Opin. Obstet. Gynecol. 26, 193–198.
Ge, S.Q., Griﬁn, J., Liu, L.H., Aston, K.I., Simon, L., Jenkins, T.G.,
Emery, B.R., Carrell, D.T., 2015. Associations of single nucleotide
polymorphisms in the Pygo2 coding sequence with idiopathic oli-
gospermia and azoospermia. Genet. Mol. Res. 14, 9053–9061.
Gorgani, N.N., Parish, C.R., Easterbrook Smith, S.B., Altin, J.G., 1997.
Histidine-rich glycoprotein binds to human IgG and C1q and in-
hibits the formation of insoluble immune complexes. Biochem-
istry 36, 6653–6662.
Guo, T., Qin, Y., Gao, X., Chen, H., Li, G., Ma, J., Chen, Z.J., 2012.
The role of male chromosomal polymorphism played in spermato-
genesis and the outcome of IVF/ICSI-ET treatment. Int. J. Androl.
35, 802–809.
Hansson, B., Westerberg, L., 2002. On the correlation between het-
erozygosity and ﬁtness in natural populations. Mol. Ecol. 11, 2467–
2474.
Hennis, B.C., Van Boheemen, P.A., Wakabayashi, S., Koide, T., Hoff-
mann, J.J., Kievit, P., Dooijewaard, G., Jansen, J.G., Kluft, C.,
1995. Identiﬁcation and genetic analysis of a common molecular
variant of histidine-rich glycoprotein with a difference of 2 kD in
apparent molecular weight. Thromb. Haemost. 74, 1491–
1496.
Jodar, M., Sendler, E., Krawetz, S.A., 2016. The protein and tran-
script proﬁles of human semen. Cell Tissue Res. 363, 85–96.
Jones, A.L., Hulett, M.D., Altin, J.G., Hogg, P., Parish, C.R., 2004.
Plasminogen is tethered with high afﬁnity to the cell surface by
the plasma protein, histidine-rich glycoprotein. J. Biol. Chem. 279,
38267–38276.
Jones, A.L., Hulett, M.D., Parish, C.R., 2005. Histidine-rich glyco-
protein: a novel adaptor protein in plasma that modulates the
immune, vascular and coagulation systems. Immunol. Cell Biol.
83, 106–118.
Kamath, M.S., Bhattacharya, S., 2012. Demographics of infertility and
management of unexplained infertility. Best Pract. Res. Clin.
Obstet. Gynaecol. 26, 729–738.
Kassaar, O., McMahon, S.A., Thompson, R., Botting, C.H., Naismith,
J.H., Stewart, A.J., 2014. Crystal structure of histidine-rich gly-
coprotein N2 domain reveals redox activity at an interdomain di-
sulﬁde bridge: implications for angiogenic regulation. Blood 123,
1948–1955.
Kovac, J.R., Pastuszak, A.W., Lamb, D.J., 2013. The use of genom-
ics, proteomics, and metabolomics in identifying biomarkers of
male infertility. Fertil. Steril. 99, 998–1007.
Laanpere, M., Altmae, S., Kaart, T., Stavreus-Evers, A., Nilsson, T.K.,
Salumets, A., 2011. Folate-metabolizing gene variants and preg-
nancy outcome of IVF. Reprod. Biomed. Online 22, 603–614.
Lash, G.E., Innes, B.A., Drury, J.A., Robson, S.C., Quenby, S., Bulmer,
J.N., 2012. Localization of angiogenic growth factors and their
receptors in the human endometrium throughout the menstrual
cycle and in recurrent miscarriage. Hum. Reprod. 27, 183–195.
Lee, C., Dixelius, J., Thulin, A., Kawamura, H., Claesson-Welsh, L.,
Olsson, A.K., 2006. Signal transduction in endothelial cells by the
angiogenesis inhibitor histidine-rich glycoprotein targets focal ad-
hesions. Exp. Cell Res. 312, 2547–2556.
Lerch, P.G., Nydegger, U.E., Kuyas, C., Haeberli, A., 1988. Histidine-
rich glycoprotein binding to activated human platelets. Br. J.
Haematol. 70, 219–224.
Liang, J., Zhang, Y., Yu, Y., Sun, W., Jing, J., Liu, R., 2014. Effect
of chromosomal polymorphisms of different genders on fertiliza-
tion rate of fresh IVF-ICSI embryo transfer cycles. Reprod. Biomed.
Online 29, 436–444.
Lindgren, K.E., Karehed, K., Karypidis, H., Hosseini, F., Bremme, K.,
Landgren, B.M., Skjoldebrand-Sparre, L., Stavreus-Evers, A.,
Sundstrom-Poromaa, I., Akerud, H., 2013. Histidine-rich glyco-
protein gene polymorphism in patients with recurrent miscar-
riage. Acta Obstet. Gynecol. Scand. 92, 974–977.
Nasah, B.T., Cox, J.N., 1978. Vascular lesions in testes associated
with male infertility in Cameroon. Possible relationship to
parasitic disease. Virchows Arch. A. Pathol Anat Histol. 377, 225–
236.
Nordqvist, S., Karehed, K., Hambiliki, F., Wanggren, K., Stavreus-
Evers, A., Akerud, H., 2010. The presence of histidine-rich gly-
coprotein in the female reproductive tract and in embryos. Reprod.
Sci. 17, 941–947.
Nordqvist, S., Karehed, K., Stavreus-Evers, A., Akerud, H., 2011a.
Histidine-rich glycoprotein polymorphism and pregnancy outcome:
a pilot study. Reprod. Biomed. Online 23, 213–219.
Nordqvist, S., Karehed, K., Stavreus-Evers, A., Akerud, H., 2011b.
Histidine-rich glycoprotein polymorphism and pregnancy outcome:
a pilot study. Reprod. Biomed. Online 23, 213–219.
Nordqvist, S., Karehed, K., Skoog Svanberg, A., Menezes, J., Akerud,
H., 2015. Ovarian response is affected by a speciﬁc histidine-rich
glycoprotein polymorphism: a preliminary study. Reprod. Biomed.
Online 30, 74–81.
187Effect of HRG polymorphism on male infertility
Obermair, A., Obruca, A., Pohl, M., Kaider, A., Vales, A., Leodolter,
S., Wojta, J., Feichtinger, W., 1999. Vascular endothelial growth
factor and its receptors in male fertility. Fertil. Steril. 72, 269–
275.
Olsson, A.K., Larsson, H., Dixelius, J., Johansson, I., Lee, C., Oellig,
C., Bjork, I., Claesson-Welsh, L., 2004. A fragment of histidine-
rich glycoprotein is a potent inhibitor of tumor vascularization.
Cancer Res. 64, 599–605.
Ozdemir, O., Yenicesu, G.I., Silan, F., Koksal, B., Atik, S., Ozen, F.,
Gol, M., Cetin, A., 2012. Recurrent pregnancy loss and its rela-
tion to combined parental thrombophilic genemutations. Genet.
Test Mol. Biomarkers. 16, 279–286.
Pinborg, A., Gaarslev, C., Hougaard, C.O., Nyboe Andersen, A., An-
dersen, P.K., Boivin, J., Schmidt, L., 2011. Inﬂuence of female
bodyweight on IVF outcome: a longitudinalmulticentre cohort study
of 487 infertile couples. Reprod. Biomed. Online 23, 490–499.
Plaseski, T., Noveski, P., Popeska, Z., Efremov, G.D., Plaseska-
Karanﬁlska, D., 2012. Association study of single-nucleotide poly-
morphisms in FASLG, JMJDIA, LOC203413, TEX15, BRDT, OR2W3,
INSR, and TAS2R38 genes withmale infertility. J. Androl. 33, 675–
683.
Poon, I.K., Hulett, M.D., Parish, C.R., 2010. Histidine-rich glycopro-
tein is a novel plasma pattern recognition molecule that recruits
IgG to facilitate necrotic cell clearance via FcgammaRI on phago-
cytes. Blood 115, 2473–2482.
Sato, Y., Tajima, A., Tsunematsu, K., Nozawa, S., Yoshiike, M., Koh,
E., Kanaya, J., Namiki, M., Matsumiya, K., Tsujimura, A., Komatsu,
K., Itoh, N., Eguchi, J., Imoto, I., Yamauchi, A., Iwamoto, T., 2015.
An association study of four candidate loci for human male fer-
tility traits with male infertility. Hum. Reprod. 30, 1510–1514.
Simantov, R., Febbraio, M., Crombie, R., Asch, A.S., Nachman, R.L.,
Silverstein, R.L., 2001. Histidine-rich glycoprotein inhibits the
antiangiogenic effect of thrombospondin-1. J. Clin. Invest. 107,
45–52.
Simantov, R., Febbraio, M., Silverstein, R.L., 2005. The antiangiogenic
effect of thrombospondin-2 is mediated by CD36 and modulated
by histidine-rich glycoprotein. Matrix Biol. 24, 27–34.
Singh, K., Jaiswal, D., 2011. Human male infertility: a complex mul-
tifactorial phenotype. Reprod. Sci. 18, 418–425.
Thornton, P., Douglas, J., 2010. Coagulation in pregnancy. Best Pract.
Res. Clin. Obstet. Gynaecol. 24, 339–352.
Tocci, A., Lucchini, C., 2010.WHO reference values for human semen.
Hum. Reprod. Update 16, 559. Author reply 559.
Vanilla, S., Dayanand, C.D., Kotur, P.F., Kutty, M.A., Vegi, P.K., 2015.
Evidence of paternal N5, N10–Methylenetetrahydrofolate Reduc-
tase (MTHFR) C677T gene polymorphism in couples with recur-
rent spontaneous abortions (RSAs) in Kolar District- A South West
of India. J. Clin. Diagn. Res. 9, BC15–BC18.
Venkatesh, T., Suresh, P.S., Tsutsumi, R., 2014. New insights
into the genetic basis of infertility. Appl. Clin. Genet. 7, 235–
243.
Vu, T.T., Stafford, A.R., Leslie, B.A., Kim, P.Y., Fredenburgh, J.C.,
Weitz, J.I., 2011. Histidine-rich glycoprotein binds ﬁbrin(ogen)
with high afﬁnity and competes with thrombin for binding to the
gamma‘-chain. J. Biol. Chem. 286, 30314–30323.
Wakabayashi, S., 2013. New insights into the functions of histidine-
rich glycoprotein. Int. Rev. Cell. Mol. Biol. 304, 467–493.
Wakabayashi, S., Koide, T., 2011. Histidine-rich glycoprotein: a pos-
sible modulator of coagulation and ﬁbrinolysis. Semin. Thromb.
Hemost. 37, 389–394.
Wake, H., Mori, S., Liu, K., Takahashi, H.K., Nishibori, M., 2009.
Histidine-rich glycoprotein inhibited high mobility group box 1 in
complexwith heparin-induced angiogenesis inmatrigel plug assay.
Eur. J. Pharmacol. 623, 89–95.
Waylen, A.L.,Metwally,M., Jones, G.L.,Wilkinson, A.J., Ledger,W.L.,
2009. Effects of cigarette smoking upon clinical outcomes of as-
sisted reproduction: a meta-analysis. Hum. Reprod. Update 15,
31–44.
Wilhelm,M., Schlegl, J.,Hahne,H.,MoghaddasGholami, A., Lieberenz,
M., Savitski, M.M., Ziegler, E., Butzmann, L., Gessulat, S., Marx,
H., Mathieson, T., Lemeer, S., Schnatbaum, K., Reimer, U.,
Wenschuh, H., Mollenhauer, M., Slotta-Huspenina, J., Boese, J.H.,
Bantscheff, M., Gerstmair, A., Faerber, F., Kuster, B., 2014. Mass-
spectrometry-based draft of the human proteome. Nature 509,
582–587.
Declaration: The authors report no ﬁnancial or commercial con-
ﬂicts of interest.
Received 8 January 2016; refereed 7 May 2016; accepted 10 May 2016.
188 KE Lindgren et al.
